Navigation Links
The right dose for oncology
Date:3/4/2013

King Mithridates understood that poison is only as good as the dosage taken. Each day, he ingested small quantities of poison in order to become immunize and escape his court's plotters. Oncologists run up against the same principle when fighting cancer. Sometimes, a small dose of chemotherapy may induce dangerous resistance mechanisms in malignant cells, resulting in relapse. Now, EPFL research published in the journal PLOS ONE reports a tool that could simply and accurately determine the right dose for individual patients.

Dosage, a vital issue

This novel tool, developed by Philippe Renaud's team at EPFL, is based on a very simple principle: a cell's electrical conductivity depends on the level of stress induced by chemotherapy. In broad terms, by measuring a cancerous cell's capacity to conduct electricity, researchers can assess the intensity of the treatment's effect.

"When chemotherapy induces very little stress in cells, particularly after the application of a small dose, there is a problem," says Robert Meissner, a co-author of the study. "Not only is its effect not sufficient to kill the affected cells, but this actually increases the risk of inducing resistance, which will eventually make the treatment ineffective."

This is vital during relapse as cells have already developed resistance mechanisms and sometimes oncologists don't have an effective alternative therapy. Hence, it is fundamental to apply the right dose from the start.

Step towards personalized oncology

The method developed at EPFL could help doctors make more patient-specific decisions. "We fully subscribe to the trend of personalized medicine," explains Philippe Renaud. "By making a simple biopsy, oncologists could test the way a particular patient's cells respond to different types of treatments at various doses."

The tool, which was designed for a clinical environment, provides a simple and fast analysis without affecting the treated cells. Unlike methods based on biomarkers, which kill cells and are extremely strenuous to perform, the EPFL technology could be implemented easily in a medical environment. In fact, scientists have already tested it on malignant breast cells treated with a standard drug, doxorubicin.

The EPFL team is currently in discussion with oncologists to continue jointly developing their procedure. Within a few months, researchers say, a startup company will likely be created to help bring the laboratory work into the hospital setting.


'/>"/>

Contact: Lionel Pousaz
lionel.pousaz@epfl.ch
41-795-597-161
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert

Related medicine news :

1. Skechers Lawsuit Filed On Behalf of Ohio Woman, Alleging That the Defective Design of Shape-Ups Caused the Plaintiff’s Serious Knee Injuries, by Wright & Schulte
2. Skechers Lawsuit Has Been Filed by Wright & Schulte on Behalf of a Pennsylvania Woman Who Allegedly Sustained Multiple Arm Fractures Allegedly Due to Shape-Ups’ Defective
3. Wright Hip Implant Lawyers at Bernstein Liebhard LLP Note Scheduling of Next Status Conference in Federal Wright Conserve Hip Replacement Litigation
4. NuvaRing Lawsuit Filed on Behalf of a South Carolina Woman who Developed Two Blood Clots While Using NuvaRing, Reports Wright & Schulte LLC
5. Skechers Injury Lawsuit Filed on Behalf of an Alabama Man Who Suffered Severe Leg Fracture Allegedly Due to Skechers Shape-Ups Toning Shoes, by Wright & Schulte LLC
6. To feed the world, give women equal rights
7. Skechers Foot Fracture Lawsuit Filed on Behalf of Nevada Woman Who Suffered a Fracture Allegedly Due to Skechers Shape-Ups Toning Shoes, Reports Wright & Schulte LLC
8. Focal Upright Furniture Announces ErgoDepot as First Retail Partner
9. Dr. Farshchian to Interview Alisha Bright on "Arthritis Show"
10. Can Brightly Colored Fruits, Veggies Protect Against ALS?
11. Brightwater Senior Living of Stonebridge, Saskatoon's Newest Personal Care and Memory Care, Is Proud To Sponsor The Alzheimer Society of Saskatchewan's Walk For Memories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... ... , ... Silicon Valley Hair Institute, the leading hair transplant center in the ... the ARTAS® hair transplant system and the younger demographic. As many younger people suffer ... methods of hair restoration. , “It can be emotionally difficult for young men and ...
(Date:9/22/2017)... ... September 22, 2017 , ... PITTSBURGH...Defibrillators are used to treat ... if one isn’t accessible in certain locations, the risk of death can be ... with this idea," said an inventor from Ridgecrest, Calif. , The MOBILE AUTOMATED ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... firm in Pennsylvania, is pleased to offer in-home and online newborn sleep ... sleep deprivation has on the body,” says company owner Courtney Zentz, a pediatric ...
(Date:9/22/2017)... ... , ... “Cursed with a Curse: The Truth about Tithing”: ... experienced when breaking free from this misconception. “Cursed with a Curse: The Truth ... by Christian Faith Publishing, Lysa M. Harrison’s new book is a powerful and ...
(Date:9/22/2017)... Francisco, CA (PRWEB) , ... September 22, 2017 ... ... way to help you brush more effectively even on the go. Their electric ... like gingivitis and gum inflammation, with UV sanitizing technology. Combining leading edge Enke ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... , Sept. 7, 2017 NuvoAir (formerly ... Spirometer, announced today a partnership with Novartis Pharma AG to ... NuvoAir,s position as the leading mobile spirometry platform and Novartis, ... ... ...
(Date:9/6/2017)... -- Robert G. Szewc, M.D., is recognized by Continental Who,s ... his contributions to the Medical field.      ... practice of Kidney and Hypertension Specialists, which specializes in ... He has worked in this position since 2002, and ... as expertise in kidneys, hypertension, chronic disease and anemia, ...
(Date:9/6/2017)... 2017 NeuroRx, a clinical stage biopharma company developing ... (ASIB), has been granted Fast Track status by the US ... (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company ... this sequential therapy targeting patients who are admitted to Emergency ... ...
Breaking Medicine Technology: